215 related articles for article (PubMed ID: 38257286)
1. Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5,6-Dihydro-4
Skoptsova AA; Geronikaki A; Novichikhina NP; Sulimov AV; Ilin IS; Sulimov VB; Bykov GA; Podoplelova NA; Pyankov OV; Shikhaliev KS
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257286
[TBL] [Abstract][Full Text] [Related]
2. New Hybrid Tetrahydropyrrolo[3,2,1-
Novichikhina NP; Shestakov AS; Medvedeva SM; Lagutina AM; Krysin MY; Podoplelova NA; Panteleev MA; Ilin IS; Sulimov AV; Tashchilova AS; Sulimov VB; Geronikaki A; Shikhaliev KS
Molecules; 2023 May; 28(9):. PubMed ID: 37175261
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-
Novichikhina N; Ilin I; Tashchilova A; Sulimov A; Kutov D; Ledenyova I; Krysin M; Shikhaliev K; Gantseva A; Gantseva E; Podoplelova N; Sulimov V
Molecules; 2020 Apr; 25(8):. PubMed ID: 32325823
[TBL] [Abstract][Full Text] [Related]
4. Innovative Three-Step Microwave-Promoted Synthesis of
Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
[TBL] [Abstract][Full Text] [Related]
5. A simple, general approach of allosteric coagulation enzyme inhibition through monosulfated hydrophobic scaffolds.
Sidhu PS; Zhou Q; Desai UR
Bioorg Med Chem Lett; 2014 Dec; 24(24):5716-5720. PubMed ID: 25453807
[TBL] [Abstract][Full Text] [Related]
6. N-Aryl-7-hydroxy-5-oxo-2,3-dihydro-1H,5H-pyrido-[3,2,1-ij]quinoline-6-carboxamides. The Synthesis and Effects on Urinary Output.
Ukrainets IV; Sidorenko LV; Golik MY; Chernenok IM; Grinevich LA; Davidenko AA
Sci Pharm; 2018 Apr; 86(2):. PubMed ID: 29642551
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
Nar H; Bauer M; Schmid A; Stassen JM; Wienen W; Priepke HW; Kauffmann IK; Ries UJ; Hauel NH
Structure; 2001 Jan; 9(1):29-37. PubMed ID: 11342132
[TBL] [Abstract][Full Text] [Related]
8. The Study of the Structure-Diuretic Activity Relationship in a Series of New
Ukrainets IV; Golik MY; Sidorenko LV; Korniyenko VI; Grinevich LA; Sim G; Kryvanych OV
Sci Pharm; 2018 Aug; 86(3):. PubMed ID: 30158453
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibitors of the blood coagulation enzymes.
Kranjc A; Kikelj D
Curr Med Chem; 2004 Oct; 11(19):2535-47. PubMed ID: 15544461
[TBL] [Abstract][Full Text] [Related]
10. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
[TBL] [Abstract][Full Text] [Related]
13. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.
Hussain Z; Cooke AJ; Neelamkavil S; Brown L; Carswell E; Geissler WM; Guo Z; Hawes B; Kelly TM; Kiyoi Y; Lai K; Lesburg C; Pow E; Zang Y; Wood HB; Edmondson SD; Liu W
Bioorg Med Chem Lett; 2020 Aug; 30(16):127072. PubMed ID: 32340773
[TBL] [Abstract][Full Text] [Related]
15. Activation of blood coagulation at heparin-coated surfaces.
Blezer R; Fouache B; Willems GM; Lindhout T
J Biomed Mater Res; 1997 Oct; 37(1):108-13. PubMed ID: 9335355
[TBL] [Abstract][Full Text] [Related]
16. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of serine proteinases from blood coagulation cascade - view on current developments.
Danalev D
Mini Rev Med Chem; 2012 Jul; 12(8):721-30. PubMed ID: 22512557
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
Samama MM
Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
[TBL] [Abstract][Full Text] [Related]
19. Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa.
Núñez-Navarro NE; Santana FM; Parra LP; Zacconi FC
Curr Med Chem; 2019; 26(17):3175-3200. PubMed ID: 29376487
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa.
Hanessian S; Larsson A; Fex T; Knecht W; Blomberg N
Bioorg Med Chem Lett; 2010 Dec; 20(23):6925-8. PubMed ID: 21035339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
